BridgeBio Pharma, Inc. (BBIO)

業務介紹

以下是英文內容的繁體中文翻譯:

BridgeBio Pharma, Inc.從事各種遺傳性疾病藥物的發現、開發和交付。該公司擁有30個發展項目的管線,包括從早期發現到後期開發階段的產品候選藥物。其正在開發的產品包括:

AG10和BBP-265,一種transthyretin(TTR)小分子穩定劑,正處於III期臨床試驗階段,用於治療TTR淀粉樣變性心肌病(ATTR-CM)。

BBP-831,一種小分子選擇性FGFR1-3抑制劑,正處於II期臨床試驗階段,用於治療兒童achondroplasia。

BBP-631,一種AAV5基因轉移產品候選藥物,正處於II期臨床試驗階段,用於治療由21-羥化酶缺乏(21OHD)引起的先天性腎上腺增生症(CAH)。

該公司還開發了Encaleret,一種鈣感受器(CaSR)的小分子拮抗劑,正處於II期臨床驗證試驗階段,用於治療常染色體顯性低鈣血症1型(ADH1)。

此外,該公司還在開發用於治療高草酸尿症和復發性腎結石患者的BBP-711。

該公司還從事孟德爾遺傳性疾病、腫瘤學和基因療法疾病產品的開發。

BridgeBio Pharma, Inc.與Leland Stanford Junior University和加州大學簽有許可和合作協議。該公司成立於2015年,總部位於加州帕羅阿爾托。



BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

公司網址

https://www.bridgebio.com